VCEL Vericel Corporation
USHealthcareAs of 2026-07-10 16:00
Why VCEL matters now
Vericel Corporation (VCEL) is a US stock in Healthcare. The latest InvestLog snapshot shows $47.00 with -2.71% on the session and $2.40B in market capitalization; recent performance reads 1-month +16.27% and YTD +11.36%.
The latest financial table shown here is Q1 2026, with revenue of $68.4M, net income of $-6.3M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E 102.43 and FCF yield 2.8%.
The latest indexable market news headline is "Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $46.00; recent insider activity includes Hopper Jonathan Mark filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
102.43
PEG
1.72
P/B
5.72
P/S
7.01
EV/EBITDA
57.66
DCF Value
$-17.45
FCF Yield
2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.8%
Operating Margin
5.4%
Net Margin
7.3%
ROE
6.4%
ROA
4.4%
ROIC
3.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $68.4M | $-6.3M | $-0.12 |
| Q4 2025 | $92.9M | $23.2M | $0.45 |
| FY 2025 | $276.3M | $16.5M | $0.32 |
| Q3 2025 | $67.5M | $5.1M | $0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$52.67
Target (Median)
$46.00
Target Range
$42.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.13
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.